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Abstract
The hereditary sensory and autonomic neuropathies (HSAN) encompass a number of inherited
disorders that are associated with sensory dysfunction (depressed reflexes, altered pain and
temperature perception) and varying degrees of autonomic dysfunction (gastroesophageal reflux,
postural hypotention, excessive sweating). Subsequent to the numerical classification of four
distinct forms of HSAN that was proposed by Dyck and Ohta, additional entities continue to be
described, so that identification and classification are ongoing. As a group, the HSAN are rare
diseases that affect both sexes. HSAN III is almost exclusive to individuals of Eastern European
Jewish extraction, with incidence of 1 per 3600 live births. Several hundred cases with HSAN IV
have been reported. The worldwide prevalence of HSAN type II is very low. This review focuses
on the description of three of the disorders, HSAN II through IV, that are characterized by
autosomal recessive inheritance and onset at birth. These three forms of HSAN have been the
most intensively studied, especially familial dysautonomia (Riley-Day syndrome or HSAN III), which
is often used as a prototype for comparison to the other HSAN. Each HSAN disorder is likely
caused by different genetic errors that affect specific aspects of small fiber neurodevelopment,
which result in variable phenotypic expression. As genetic tests are routinely used for diagnostic
confirmation of HSAN III only, other means of differentiating between the disorders is necessary.
Diagnosis is based on the clinical features, the degree of both sensory and autonomic dysfunction,
and biochemical evaluations, with pathologic examinations serving to further confirm differences.
Treatments for all these disorders are supportive.
Background
Although genetic disorders affecting the sensory and auto-
nomic nervous systems are rare, their existence provides a
means of furthering our knowledge regarding a very com-
plex part of the nervous system. The close relationship
between development and survival of the sensory and
autonomic nervous system is especially well illustrated in
the diversity of a group of genetic disorders known as
Hereditary Sensory and Autonomic Neuropathies
(HSAN) [1].
Classification of the various sensory disorders is unsettled
and ongoing. In addition to the four numerical subtypes
proposed by Dyck and Ohta [2], additional entities have
been described [1,3] and there is semantic controversy.
For example, familial dysautonomia (FD), originally the
Riley Day syndrome [4], is also referred to as HSAN III and
hereditary sensory neuropathy with anhidrosis is also
referred to congenital insensitivity to pain with anhidrosis
(CIPA) or HSAN IV (Table 1). Each HSAN disorder is
likely caused by different genetic errors that affect specific
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aspects of small fiber neurodevelopment, which result in
variable phenotypic expression. Because genetic tests are
not available for all of the HSAN disorders, other means
of differentiating between the disorders is necessary.
Although specific neuropathological features have been
described for some of the disorders, obtainment of neuro-
logical tissue is invasive and not always feasible. Thus clin-
ical examinations with careful assessment of sensory and
autonomic functions are preferable.
The genes have been cloned for HSAN types III and IV and
autosomal recessive inheritance demonstrated. For type
HSAN type II, new information is available suggesting
that this disorder has a similar autosomal recessive inher-
itance. Penetrance is always complete in all three types but
disease expression is variable. The impediment to neuro-
nal development starts in utero, and thus clinical features
such as poor suck, hypotonia, and temperature instability
are usually present in the neonatal period. Furthermore,
the lack of an axon flare in response to intradermal hista-
mine is so universal and consistent in patients with HSAN
II, III, and IV that it is considered one of the clinical diag-
nostic criteria. Nonetheless, diagnosis may be delayed in
some individuals to late infancy or early childhood when
injuries, enteric dysfunction, or delayed milestones
become evident. Although the development of the unmy-
elinated neuronal population is impeded in all three
HSAN types, the degree of involvement will vary with the
particular HSAN type. Accordingly, pain and temperature
perception and autonomic dysfunction will vary and also
affect age of diagnosis and presentation (Table 2).
This review discusses diagnosis, neuropathology, and
clinical expression of the HSAN disorders in general, as
well as the specific characteristics that help differentiate
the three most common disorders, HSAN II through IV, as
they have been the most intensively studied.
Genetics
With the exception of hereditary sensory radicular neu-
ropathy (HSAN I), which presents in the second decade
and is transmitted as a dominant disorder, the other
HSAN are present at birth and are transmitted as auto-
somal recessive disorders (Table 1). HSAN I has been
associated with a mutation in the SPTLC1  gene which
encodes for serine palmitoyltransferase – the rate limiting
enzyme for the synthesis of the sphingolipids, ceramide
and sphingomyelin. [5,6]. Other HSAN with specific
genetic mutations are HSAN III (FD) and HSAN IV
(CIPA), which are transmitted as autosomal recessive dis-
orders.
FD is almost exclusive to individuals of Eastern European
Jewish extraction [7-9]. In this population the carrier rate
is estimated as approximately 1 in 30 with a disease inci-
dence of 1 per 3600 live births [10]. In 1993 the FD gene
was localized to the long arm of chromosome 9 (9q31)
[11]. In 2001 the gene was cloned. A single point muta-
tion was identified on the IKBKAP gene and greater than
99% of affected individuals are homozygous for this com-
mon mutation that occurs within intron 20. The result is
tissue-specific mis-splicing which results in decreased
amounts of normal transcript, especially in neuronal tis-
sue. Therefore, there is a predicted lack of expression of
the normal protein product, IKAP [7,8].
IKAP is a subunit of the highly conserved complex Elon-
gator, which is involved in transcriptional elongation.
Recently, RNA interference studies have shown that deple-
tion of IKAP, and thus Elongator, results in reduced tran-
scriptional elongation of several target genes via histone
H3 hypoacetylation. A subset of these target genes are
required for cell motility, and FD patient cells were shown
to be defective in cell migration assays, suggesting that
defective cellular motility may underlie the developmen-
tal neuropathology of FD. Furthermore, studies in yeast
suggest that the Elongator complex is involved in exocyto-
sis and tRNA modification and studies in mammalian
cells implicate IKAP as a scaffold protein involved in cyto-
plasmic JNK activation in response to extracellular stress.
IKAP's role in these processes, and how they relate to the
FD phenotype, is not yet understood.
Table 1: Genetics of Hereditary Sensory and Autonomic Neuropathies (HSAN)
Nomenclature * HSAN type Transmission Chromosomal location Gene
Hereditary sensory radicular neuropathy I AD 9q22.1-22.3 SPTLC1
Congenital sensory neuropathy (CSN) II AR 12p13.33 HSN2 (?)
Familial dysautonomia (FD)/Riley Day III AR 9q31 IKBKAP
Congenital insensitivity to pain with anhidrosis (CIPA) IV AR 1q21-22 NTRK1 (TRKA)
Congenital insensitivity to pain with partial anhidrosis V NK NK NTRK1
Congenital autonomic dysfunction with universal pain loss (CAD) NK NK
Progressive panneuropathy NK NK
• * HSAN nomenclature from Dyck and Ohta [2]
• NK: not known, AR: autosomal recessive, AD: autosomal dominantOrphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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Two other missense mutations that cause FD have been
reported. One mutation, in exon 19, was noted in four
unrelated Jewish patients heterozygous for the major
splice mutation [7,8]; the second mutation, in exon 26,
was reported in a single patient who was also hetero-
zygous for the major splice mutation but inherited the
new mutation from a non-Jewish parent [9]. FD is the
only HSAN for which genetic testing is commercially
available.
HSAN IV is caused by mutations in the NTRK1 (TRKA)
gene that is located on chromosome 1 (1q21-q22). This
gene encodes for neurotrophic tyrosine kinase receptor
type 1 that is autophosphorylated in response to NGF
(nerve growth factor) [12]. As a result of loss of function
mutations, signal transduction at the NGF receptor is
impeded and NGF dependent neurons, the small sensory
and sympathetic neurons, fail to survive. There does not
seem to be a particular ethnic distribution for this reces-
sive disorder but onehalf of reported cases have occurred
in consanguineous marriages [1,12,13]. As many muta-
tions have been described, commercial molecular genetic
diagnostic testing is not yet feasible.
Specific genetic mutations have not been identified for the
other HSAN disorders, although there is some evidence
that a mutation in the NTRK1 gene also may be responsi-
ble for HSAN V [14].
The other HSANs including HSAN II, are presumed to be
autosomal recessive disorders or de novo dominant muta-
tions. In each of the disorders, other siblings but not par-
ents have been affected. None of the disorders has a sex
preference or particular ethnic distribution.
Clinical features, diagnosis and treatment
For each of the HSAN disorders, penetrance is complete
but there can be marked variability in expression. Diagno-
sis is based upon clinical features as well as the degree of
both sensory and autonomic dysfunction. In order to dif-
ferentiate between the HSAN, quantitative assessment of
function as well as identification of particular clinical
characteristics is required. Unique to all HSAN, is lack of
Table 2: Major clinical features of HSAN II, HSAN III, and HSAN IV
Clinical features HSAN type II HSAN type III HSAN type IV
Onset Birth Birth Birth
Initial symptoms (From birth to 
age 3 years)
Swallowing problems Swallowing problems Fevers
Self mutilation (65%) Aspiration pneumonia Self mutilation (88%)
Delayed development Breech presentation (37%)
Hypothermia
Delayed development
Unique features No axon flare No axon flare No axon flare
Lack of fungiform papilla Lack of fungiform papilla Anhydrosis
Hearing loss (30%) Alacrima Consanguinity 50%
Sensory dysfunction
Depressed DTR Frequent (71%) Almost consistent (99%) Infrequent (9%)
Pain perception Absent Mild to moderate decrease Absent
Temperature perception Severe decrease Mild to moderate decrease Absent
Vibration sense Normal Normal Normal to moderate decrease
Autonomic
Gastroesophageal Reflux Frequent (71%) Frequent (67%) Uncommon (24%)
Postural hypotension Uncommon (25%) Almost consistent (99%) Uncommon (29%)
Episodic hypertension Rare Frequent Rare
Ectodermal features
Dry Skin No No Consistent
Fractures 29% 40% 71%
Scoliosis 59% 85% 23%
Intelligence
IQ < 65 Common (38%) Uncommon (10%) Common (33%)
Hyperactivity Common (41%) Uncommon Common (54%)
Rare < 1%
Infrequent < 10%
Uncommon < 30%
Common 30–65%
Frequent > 65%
DTR = deep tendon reflexesOrphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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a normal axon flare in response to intradermal histamine
phosphate (Figure 1). As can been seen in Figure 1, when
a quantity of 0.1 ml of histamine is injected intradermally
using a fine needle and tuberculin syringe (concentration
= 0.275 mg histamine phosphate/ml) in a normal subject,
the result is a bright red histamine flare due to capillary
vasodilatation within five minutes. This normal effect is
due to axon reflex within dermal nerves. Because the nor-
mal axon flare response depends on activation of unmy-
elinated C-fibers, in some mild cases of HSAN II patients
who have largely preserved C-fibers or some HSAN V
patients who have little reduction of C-fibers, the hista-
mine test may be normal. However, there are other fea-
tures that assist in distinguishing the disorders (Table 2).
Congenital sensory neuropathy (HSAN II)
Clinical presentation
HSAN II presents in infancy or early childhood and is
nonprogressive. It is characterized by profound and uni-
versal sensory loss and marked hypotonia. HSAN II occurs
sporadically or with autosomal recessive inheritance.
There is no sex preference or particular ethnic preponder-
ance, and to date there is no increased incidence of con-
sanguinity.
Although the disorder is associated with profound sensory
loss involving large and small fiber modalities, the earliest
problems are caused by autonomic dysfunction [1-3,15-
17]. The neonatal course is characterized by severe feeding
problems and frequent apnea [15-17]. Gastroesophageal
reflux occurs commonly. Other autonomic disturbances,
such as erythematous blotching of the skin and postural
hypotension, have not been observed. Episodic hyperhy-
drosis as well as patchy areas of anhidrosis can occur in
the same patient. Overflow tearing is frequently delayed
but is eventually normal. Pupils have an exaggerated
response to parasympathomimetic agents.
All peripheral sensations are affected but distribution of
somatic involvement may vary. Pain, temperature, and
position senses are involved. Trophic changes are present
in the upper and lower extremities. At one time, HSAN II
was termed 'Morvan's disease' (after the physician who first
described the disease and the occurrence of 'painless whit-
lows' or acrodystrophic neuropathy [18,19]. HSAN II is
associated with frequent occurrence of unrecognized inju-
ries and fractures of hands, feet, and limbs, as well as
Charcot joints [1,17,19].
Selfmutilation may begin as early as four months of age
and is usually associated with eruption of primary denti-
tion [20]. Taste sensation is diminished and lingual fungi-
form papillae are hypotrophic. Corneal and gag reflexes
may be diminished. Deep tendon reflexes are attenuated
and hypotonia is common which delays attainment of
developmental milestones and may contribute to scolio-
sis. Despite the marked sensory abnormalities, other
aspects of the neurological examination may be normal
Histamine test Figure 1
Histamine test. Dysautonomic reaction (forearm on top) demonstrates a narrow areola surrounding the wheal. Normal reac-
tion (lower forearm) displays diffuse axon flare around a central wheal.Orphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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including mental function, cranial nerves, cerebellar and
motor functions. Although the tendon reflexes are
decreased or absent, there is no muscle atrophy or muscle
weakness.
Pathology
Sural nerve biopsy reveals a marked reduction in nerve
size and depletion of large and small myelinated fibers
but only a slightly decreased number of unmyelinated fib-
ers [16,19]. No cutaneous sensory receptors or nerve fib-
ers are seen but catecholaminergic sympathetic fibers can
be demonstrated by aldehydeinduced fluorescence [19].
Diagnosis
As there is no DNA molecular testing available, diagnosis
is based on documenting profound peripheral sensory
involvement of both peripheral and cranial nerves, which
includes an absent axon flare after intradermal histamine.
Clinical identification is made by the finding of a mutilat-
ing acropathy with a severe, distally pronounced impair-
ment of all sensory qualities that includes light touch
sensation, position sense and vibratory perception, as well
as pain and temperature perception. Supportive evidence
includes selfmutilation, hypotonia and delayed mile-
stones, and normal somatic growth.
The neurophysiological evaluation shows abnormal
vibratory thresholds, and quantitative sensory testing may
also reveal elevated thermal thresholds at the hands and
feet [16]. Typically, nerve conduction studies confirm
severe impairment of sensory nerve conduction velocities
and absent sensory nerve action potentials, but motor
nerve conduction velocities are at or slightly below the
normal limit and compound motor action potentials may
only have slightly reduced amplitudes [16,19]. According
to Dyck, the electromyogram (EMG) shows minimal
fibrillations and a rarified pattern with maximal volitional
innervation as well as an increased number of polyphasic
motor action unit potentials [16]. Electroencephalo-
graphic (EEG) studies are normal, but auditory evoked
potentials indicate immature pathways.
Management
Management is symptomatic and preventative. If feeding
problems compromise nutrition and if gastroesophageal
reflux is also present, fundoplication with gastrostomy is
recommended. Sleep pneumograms can determine if
there is central apnea and if respiratory support is needed.
Parents and patients education is required to learn how to
avoid injury and to be alert for signs of unrecognized
trauma.
Familial dysautonomia (FD, HSAN III, or Riley-
Day syndrome)
Clinical Presentation
HSAN III is the most common of the HSAN disorders. It
is present at birth and it is progressive [21,22]. Because the
effects of the autonomic nervous system are pervasive,
there are protean secondary functional abnormalities that
result in multisysytem dysfunction. Clinical expression
varies widely from individual to individual as does disease
progression, even within the same family. The child with
familial dysautonomia is not born with any obvious dys-
morphism but a characteristic facial expression may
develop over time that appears to be due to the effects of
facial tone on bone development. The facies appear more
similar with advancing age and there is a curious flatten-
ing of the upper lip that is most obvious when smiling
(Figure 2). Other common physical characteristics are due
Facial features Figure 2
Facial features. Facial features of a patient with HSAN over time. Note flattening of upper lip. By age 10 years prominence of 
lower jaw is apparent and by age 19 years there is mild erosion of right nostril due to inadvertent self-mutilation.Orphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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to orthopedic problems such as severe kyphoscoliosis and
short stature (Figure 3).
Autonomic manifestations are prominent, involve
peripheral and central tracts, and impose the greatest
impediments to function [22]. Although absence of tears
(alacrima) with emotional crying is one of the cardinal
features of the disorder, this sign may not be immediately
recognized since lack of overflow tears is normal until
about seven months of age. Thus the earliest sign of auto-
nomic dysfunction usually is feeding difficulties. Oral
incoordination results in a poor suck and misdirection of
the bolus and gastroesophageal reflux cause recurrent
aspiration pneumonia that can result eventually in
chronic lung disease. Compounding the problem of aspi-
ration pneumonias and chronic lung disease is the pres-
ence of relative insensitivity to hypoxemia [23-26], which
limits ability to cope with pneumonia or even travel to
high altitudes where there is reduced partial pressure of
oxygen. Ensuing hypoxemia may lead to hypotension,
bradyarrhythmia and even syncope. FD patients also
exhibit protracted episodes of nausea and vomiting that
are termed the 'dysautonomic crisis', a constellation of
symptoms with abnormal gastrointestinal motility being
only one aspect. During the crisis there are cardiovascular
changes including hypertension, tachycardia and blotch-
ing. There is a generalized increase in secretions resulting
in excessive diaphoresis, gastrorrhea, bronchorrhea and
hypersalivation with copious drooling. In addition there
are negative personality changes that can range from irri-
tability and withdrawal to general excitation with pacing
and picking at the skin. Forty percent of individuals with
FD manifest a cyclical crisis pattern with frequencies that
can occur daily, weekly, or monthly. In these individuals
the crisis is most likely to follow morning arousal. How-
ever, with sufficient stress, a crisis can be observed in any
affected individual. The stress can be emotional secondary
to anxiety or the stress can be physiologic secondary to
infection, surgery, sleep deprivation, excessive fatigue, or
visceral pain secondary to constipation or menses.
The individual with familial dysautonomia commonly
experiences orthostatic hypotension without a compensa-
tory tachycardia, as well as episodic and supine hyperten-
sion [22,27]. Orthostatic change in blood pressure is a
cardinal sign of autonomic insufficiency. In FD individu-
als, the lack of compensatory tachycardia is believed due
to decreased sympathetic innervation of the vasculature
with subsequent inability to increase plasma norepine-
phrine in response to standing or exercise [28]. Clinical
manifestations of orthostatic hypotension include presyn-
cope: episodes of lightheadedness, dizzy spells, and blur-
ring of vision. Some patients complain of "weak legs." On
occasion, there may be syncope. Symptoms tend to be
worse in the morning, in hot or humid weather, when the
bladder is full, before a large bowel movement, after a
long car ride, coming out of a movie theater, or with
fatigue. Infection and dehydration can compound symp-
toms. Generally, low blood pressure is more troublesome
in the adult years and can greatly limit function and
mobility.
The dysautonomic patient can also experience episodic
hypertension in response to emotional stress or visceral
pain or as part of the crisis constellation. The episodic
hypertension is thought to be caused by central release of
catecholamines and exaggerated peripheral responses due
to denervation hypersensitivity, as supersensitivity to
cholinergic and adrenergic agents has been demonstrated
[29,30]. Hypertension is also more apt to occur when the
patient is supine and again this may be due to exaggerated
responses due to denervation hypersensitivity as the nore-
pinephrine levels are not extraordinarily high in this posi-
tion. Further manifestations of vasomotor and
cardiovascular perturbations include erythematous skin
blotching and hyperhydrosis with excitation or even eat-
ing.
The sensory abnormalities in individuals with FD are not
as profound as with the other HSAN disorders and self-
mutilation is rare. Pain and temperature perception are
decreased but not absent [21,31]. While bone and skin
pain are poorly perceived, sensitivity to visceral pain has
been observed. There are appropriate responses to pleural
effusions, esophageal irritation, and menstrual cramping.
Corneal and tendon reflexes are hypoactive, and taste
appreciation is diminished which is due to absence of lin-
gual fungiform papillae. Later in the course of the illness,
vibratory sensory loss and impaired coordination appear
Kyphoscoliosis in a 10-year-old girl with HSAN III Figure 3
Kyphoscoliosis in a 10-year-old girl with HSAN III.Orphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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[21]. Somatic growth is poor and by 10 years of age, 85%
of patients have scoliosis [32] (Figure 3).
Developmental milestones are commonly delayed as a
result of infantile hypotonia and poorly graded move-
ments. Although receptive language is usually normal,
expressive speech is delayed and often is poorly articu-
lated or nasal in quality. Performance on standardized
intelligence tests frequently demonstrates better verbal
than motor performance [33]. Executive planning and
organizational skills tend to be poor. Seizures with decer-
ebrate posturing can follow breathholding even in chil-
dren with normal EEG findings.
There is pathological and clinical evidence that FD is asso-
ciated with neurological progression. The question is
whether this progression is inherent to the disorder or is
secondary to some of the other problems such as cardio-
vascular lability. In older patients, central neuropathology
has not been documented but Magnetic Resonance Imag-
ing (MRI's) frequently show generalized atrophy includ-
ing the cerebellum. This may contribute to worsening of
the ataxic gait and greater balance problems requiring the
use of walkers or wheelchairs in the older patients. In
some FD adults changes have also been noted in mental
processing that can range from poor concentration to
phobias to the rare occurrence of actual dementia [34].
There is also progressive optic nerve atrophy that severely
limits vision in the older patients [35].
It is possible that compromised cerebral perfusion may
contribute to the neurological progression with age as
other cardiovascular perturbations worsen with age such
as more pronounced problems with postural hypotension
and worsening supine hypertension, development of
ischemic glomerulosclerosis [36] and cardiac arrhythmias
[37]. Supporting this hypothesis are the observation by
Hilz et al of decreased or inappropriate cerebral blood
flow under various conditions including tilt as well as
hypoxia and hypercapnia [26,38,39]. Thus some of the
neurological progression might be avoided with better
management of blood pressure lability.
Fertility in both males and females has been proven, and
offspring of affected individuals have been normal [40].
Progressive diminution of renal function with age is a fre-
quent observation [36,41]. Moderate azotemia is an early
sign. Creatinine clearance decreases, and many patients
have subnormal renin excretion. Nephrosclerosis has
been reported on autopsy [36]. Despite these multiple
problems, with improved supportive and preventative
measures about half of the patients now reach adulthood
[35,42].
Pathology
Familial dysautonomia was originally reported as "central
autonomic dysfunction with absent lacrimation" [4], yet
consistent neuropathological findings all have been
restricted to the periphery [43] and the information
derived suggests that familial dysautonomia results from
incomplete development of the sensory and autonomic
systems, as well as limited survival of sensory and auto-
nomic neurons, with sympathetic development more
widely affected than parasympathetic. Overall there are
decreased numbers of unmyelinated and small myeli-
nated neurons. The sural nerve is hypoplastic and con-
tains markedly reduced populations of nonmyelinated
and small myelinated fibers, and there is lesser depletion
of largemyelinated axons [44,45]. Neuron somas in the
Gasserian and spinal ganglia are reduced to 50% of the
normal number and neuron somas in cervical and tho-
racic sympathetic ganglia are reduced to 27%–37%
[43,46]. The reduced size of cervical and thoracic ganglia
is consistent with cardiac autonomic dysfunction. Sympa-
thetic terminals are sparse or absent on vessels of skin,
which probably contributes to vasomotor lability [47,48].
Increasing residual nodules and decreasing neurons in
older patients indicate a degenerative component. The
dorsal columns conducting vibration, proprioceptive and
touch information are initially normal but diminish
markedly in older patients [46]. Parasympathetic ganglia
are variably affected; the ciliary ganglion is normal or mar-
ginally depleted of neurons but the sphenopalatine gan-
glion has less than one tenth of that in the normal
population. Consistent qualitative central nervous system
(CNS) anomalies have not been found. However, there is
increasing clinical evidence for central autonomic dys-
function and new genetic findings indicate that central
regions have altered expression of the normal gene prod-
uct [49]. Thus we assume that pathologic confirmation of
central defects will eventually be provided.
Diagnosis
Diagnosis is based upon clinical recognition of both sen-
sory and autonomic dysfunction. The combination of the
"cardinal" criteria, i.e. alacrima, absent fungiform papillae
(Figure 4), depressed patellar reflexes, and abnormal his-
tamine test (Figure 1) in an individual of Ashkenazi Jew-
ish extraction is usually sufficient to make the diagnosis.
As individuals affected with the other HSANs also fail to
produce an axon flare after intradermal histamine [1],
careful assessment of the other clinical signs and symp-
toms is necessary in order to distinguish between these
disorders. Because there can be extreme variability in
expression, clinical criteria are not always sufficient so
that DNA molecular diagnostics should be performed to
provide a definitive diagnosis. FD is the only HSAN for
which commercially available genetic testing is available.Orphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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Management
Although gene identification holds the promise of eventu-
ally yielding more specific treatments for this disorder, at
present treatments remain supportive and directed toward
specific problems that vary considerably from patient to
patient [50,51]. In particular there are four areas that
remain extremely problematic as they can severely limit
independent function. These are alacrima, gastrointestinal
dysfunction, respiratory dysfunction, and blood pressure
lability. These problems continue to challenge the treating
physician and provide the impetus to find definitive ther-
apy for this disorder.
Alacrima
Alacrima in combination with corneal analgesia predis-
pose the eye to development of corneal ulcerations and
scarring. Frequent administration of topical lubricants is
used to prevent corneal complications [35]. Cautery of the
tear ducts also helps to increase baseline moisture. For the
most part, corneal transplants have had a poor success
rate.
Gastrointestinal dysfunction
Gastrointestinal dysmotility includes oropharyngeal inco-
ordination, abnormal esophageal peristalsis, erratic gas-
tric emptying, gastroesophageal reflux and the episodic
protracted vomiting attacks termed "dysautonomic cri-
ses". Fundoplication with gastrostomy is often necessary
to compensate for the oral incoordination and gastro-
esophageal reflux as the procedure helps maintain ade-
quate caloric intake, avoids dehydration, and minimize
aspiration. Treatment of the dysautonomic crisis is a
greater challenge because therapeutic intervention is two-
fold, directed toward the brain as well as the gastrointesti-
nal tract. Many of the triggers are induced by central
insults, but the prominent manifestations are gastrointes-
tinal. Thus the concept has been proposed that the crisis
may represent a type of autonomic seizure and that nau-
sea may be the aura [52]. This hypothesis was supported
by SPECT studies demonstrating areas of enhanced per-
fusion in the temporal area during crises. The hypothesis
that crisis is a type of autonomic seizure is consistent with
the clinical experience; typical antiemetic medications are
not as effective in treating the episodes. However, cen-
trally acting agents such as the benzodiazepines lock the
GABAA receptor into a conformation where the neuro-
transmitter GABA has a much higher affinity for the recep-
tor, thus increasing the frequency of opening of the
associated Chloride ion channel and hyperpolarizing the
membrane. This action potentiates the inhibitory effect of
the available GABA leading to sedatory and anxiolytic
effects. Thus the medications that are used to control the
crisis are GABA enhancing agents central alpha-adrenergic
agonists such as clonidine, and anticholinergics such as
cyproheptadine [50,51].
Respiratory dysfunction
There are three potential factors that can compromise res-
piratory function and contribute to increased morbidity
and mortality in the individual with familial dysautono-
mia – chronic lung disease secondary to repeated aspira-
tions, restrictive lung disease imposed by scoliosis and
muscle weakness, and chemoreceptor dysfunction result-
ing in blunted responses to hypoxemia.
The most effective means of avoiding chronic lung disease
secondary to aspiration is to carefully assess oral coordi-
nation. Cineradiographic swallowing studies using vari-
ous food consistencies often demonstrate that thin liquids
are more apt to be aspirated than softer foods or thickened
liquids. Cineradiographic studies, or esophageal pH stud-
ies, provide further information regarding gastroesopha-
geal reflux, which is another potential source of aspiration
pneumonia. Due to the frequent combination of oral
incoordination and gastroesophageal reflux, medical
management with prokinetic agents, proton pump inhib-
itors, thickening of feeds, and even positioning often is
A. Normal tongue with fungiform papillae present on the tip Figure 4
A. Normal tongue with fungiform papillae present on the tip. B. Dysautonomic tongue. Note the absence of the highly vascular-
ized fungiform papillae from the tongue tip, which gives the appearance of a smooth tongue.Orphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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not adequate. Thus fundoplication with gastrostomy is
commonly recommended [50,51].
Restrictive lung disease is imposed by the frequent occur-
rence of spinal curvature. Annual examination of the
spine should be implemented to prevent severe deform-
ing curves and exercise of the hypotonic intercostal mus-
cles is essential for maintaining adequate vital capacity. If
brace therapy is not successful in halting progression, or if
the brace itself inhibits respiratory excursion, or if the
curve is severe, spinal fusion is recommended [32,50].
Another component of respiratory dysfunction is
decreased chemoreceptor and baroreceptor sensitivity,
which severely compromises ability to cope with respira-
tory infections, and other potential causes of hypoxia [23-
26]. FD individuals do not appropriately increase minute
ventilation in hypoxic or hypercapnic situations such as
high altitudes, pressurized airplane cabins or with inter-
current pneumonia. Even underwater swimming poses a
potential threat. Therefore a high index of suspicion for
pneumonia should be maintained rather than attributing
febrile episodes to autonomic dysfunction with tempera-
ture dysregulation. Appropriate instructions need to be
given regarding air travel and travel to high altitudes.
Blood pressure lability
The individual with familial dysautonomia commonly
experiences postural hypotension without compensatory
tachycardia as well as episodic hypertension and supine
hypertension [27]. Treatments for orthostatic hypoten-
sion include hydration, exercise and use of various medi-
cations [50,51]. Adequate hydration can also be
monitored by blood urea nitrogen levels. Lower extremity
exercises are encouraged to increase muscle tone and pro-
mote venous return. Other treatments have included
wearing of elastic stockings, additional salt in the diet, and
use of fludrocortisone, a mineralocorticoid, and mido-
drine, a peripheral alpha adrenergic agonist [53,54].
Fludrocortisone 0.1 mg is given in the morning. A second
dose is often added at midday. Midodrine is also given in
the morning at 0.05–0.1 mg/kg per dose and is usually
repeated every 4 hours. It should be stopped within four
hours of bedtime.
Hypertension appears to be better tolerated than hypoten-
sion. As blood pressure is so labile and so susceptible to
positional changes, treatment for hypertension should be
instituted only when hypertension is refractory or associ-
ated with headache or symptoms of crisis, such as nausea
or agitated activity. At such times, treatment is usually
instituted with diazepam or clonidine [50,51].
Congenital insensitivity to pain with anhidrosis 
(CIPA; HSAN IV)
Clinical Presentation
HSAN IV is the second most common HSAN and like the
other recessively transmitted HSAN onset is in infancy [1-
3]. Several hundreds cases of HSAN IV have been pub-
lished. What distinguishes HSAN IV is the extensive
involvement of ectodermal structures including skin,
bone and nervous system, especially absent or markedly
decreased sweating, the cardinal feature of the disorder.
HSAN type IV is characterized by anhidrosis, absent or
markedly decreased sweating [1-3,12,13,55-58]. It is the
anhidrosis that causes episodic fevers and extreme hyper-
pyrexia that is usually the earliest sign of the disorder and
can cause recurrent febrile convulsions secondary to high
environmental temperature [1,12]. The anhidrosis is
probably secondary to impaired thoracolumbar sympa-
thetic outflow. It is present on the trunk and upper
extremities in 100% of cases, whereas other areas of the
body are variably affected. It causes the skin to become
thick and callused with lichenification of palms, dys-
trophic nails, and areas of hypotrichosis on the scalp
[12,13,56,57].
Like FD, HSAN IV is associated with decreased sensation
and autonomic dysfunction. It may be confused with FD
in the neonatal period but the differences become much
clearer with time as the characteristic anhidrosis causes
cutaneous changes and the sensory insensitivity is much
more profound resulting in self-mutilation, auto-amputa-
tion, and corneal scarring [1,3,12,56,57]. Although there
is no immunological problem, individuals with HSAN IV
have definite problems in healing of ectodermal struc-
tures – skin and bone. Fractures are slow to heal and large
weight bearing joints appear particularly susceptible to
repeated trauma and frequently go on to the development
of Charcot joints and osteomyelitis (Figure 5). Speech is
usually clear. Although hypotonia and delayed develop-
mental milestones are frequent in the early years, strength
and tone normalize with age. However, there can be
severe learning problems. Hyperactivity and emotional
lability are common [1,3,12,56].
Other than the characteristic anhidrosis, other autonomic
perturbations are mild to absent. Although patients
exhibit myosis with dilute intraocular mecholyl, emo-
tional tearing is normal [1,3]. Postural hypotension with
compensatory tachycardia may be present but not epi-
sodic hypertension suggesting that the blood pressure
problems are secondary to disuse atrophy rather than
sympathetic dysfunction. There is none to minimal gas-
trointestinal dysmotility; vomiting is not a feature of the
disease and cyclical crises do not occur. Insensitivity to
hypoxia and hypercapnia has not been noted. However,Orphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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patients may have a heightened sympathetic response, as
erythematous blotching of the skin with excitement has
been seen in younger patients. Acrocyanosis is notably
lacking. Gastrointestinal dysmotility is infrequent; vomit-
ing is not a feature of the disease and cyclical crises do not
occur [1,3]. Insensitivity to hypoxia and hypercapnia has
not been noted.
Pathology
Neuropathological studies have demonstrated decreased
neuronal populations. Sural nerve biopsies show myeli-
nated nerve fibers are present but unmyelinated fibers are
absent [2]. Skin biopsy morphology of HSAN IV patients
reveals deficient C and Aδ fibers in the epidermis and
absent or hypoplastic dermal sweat glands without inner-
vation [59-62].
Although sweat glands can be demonstrated in skin biop-
sies, unmyelinated fibers are not adjacent to sweat glands
[2,59-62]. The lack of sweat gland innervation accounts
for the clinical manifestation of severe anhidrosis and the
objective absence of sympathetic skin responses (SSR)
[63]. Although central neuropathology has not been dem-
onstrated for HSAN type IV, affected individuals have clin-
ical features suggesting central involvement as the patients
are frequently exhibit hypotonia and delayed develop-
mental milestones in the early years and there can be
severe learning problems, often associated with hyperac-
tivity [1,12,58].
Diagnosis
It has been suggested that diagnosis of this disorder
requires three clinical criteria, i.e. anhidrosis, decreased
pain perception and mental retardation [12]. However,
our experience indicates that the degree of expression of
the three clinical features, especially intellectual ability,
can be extremely varied. In addition to the absence of an
axon flare following intradermal histamine, which is com-
mon to all the HSAN, clinical diagnosis is primarily based
on the fact that HSAN IV is the only HSAN that is associ-
ated with widespread anhidrosis. The sensory abnormali-
ties are also profound and widespread. They include
cranial nerves and visceral sensation resulting in insensi-
tivity to superficial as well as deep, visceral painful stimuli
and in impressive self-mutilation and traumatized joints.
Temperature sensation is also decreased or absent but
deep tendon reflexes are usually intact. Although there has
been gene identification, numerous mutations does not
allow simple DNA diagnosis so that it is not routinely
used for clinical confirmation of diagnosis [12,13]. Pene-
trance is complete, but expression varies widely and may
be related to the site of the mutation on the NGF receptor
or whether there is genetic homo- or heterozygosity [55].
Management
Medical management is supportive and oriented to con-
trol of hyperthermia, prevention of self-mutilation and
treatment of orthopedic problems that potentially can
cause severe and debilitating deformities. In addition it is
also necessary to help families cope with behavior and
educational issues. Febrile spikes will respond to use of
acetaminophen and/or ibuprofen or direct cooling in a
bath or cooling blanket. Diazepam, which is used for FD
patients, has not been as effective in CIPA patients; chlo-
rpromazine or chloral hydrate is more effective in relaxing
the children and allowing them to cool. Careful daily
inspection for unrecognized injury is important. Braces
may be required on the ankles to prevent injury to these
weight bearing joints. Some children will require smooth-
ing of the teeth or extraction to prevent self-mutilation of
the tongue and lips. Irritability, hyperactivity, and suscep-
tibility to rages are seen in about 50% of patients. Chlo-
rpromazine has been helpful as well as behavior
modification. The prognosis for independent function
depends on the degree of disease expression and the abil-
ity to control the secondary clinical problems.
Charcot joints are demonstrated in this boy with HSAN IV  or congenital insensitivity to pain with anhidrosis (CIPA) Figure 5
Charcot joints are demonstrated in this boy with HSAN IV 
or congenital insensitivity to pain with anhidrosis (CIPA). The 
left knee and left ankle are enlarged and distorted. The skin 
over the medial aspect of the ankle is darkened with a drain-
ing would secondary to superimposed osteomyelitis. There 
are other areas of trauma and ulcers including a site on the 
left heel.Orphanet Journal of Rare Diseases 2007, 2:39 http://www.OJRD.com/content/2/1/39
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Prognosis and goals
There are a number of hereditary and sensory and auto-
nomic neuropathies (HSAN). Identification and classifi-
cation of these entities is an ongoing process and will be
refined as we become more exact in clinical acumen,
definitive autonomic testing, pathological examinations
and finally molecular evaluations. As genetic tests for spe-
cific diagnosis are developed, genetic counseling will be
more specific and we will gain insight as to how to pro-
vide more definitive therapies.
Prognosis for the HSAN disorders is improving and they
can no longer be considered only as diseases of child-
hood. With greater understanding of the various disorders
and development of treatment programs, increasing num-
bers of patients are reaching adulthood. The goal is now
to help them achieve independent function with minimal
physical limitations. As the disorders are so rare, centrali-
zation of care increases our ability to diagnose patients
accurately, understand the natural progression of the dis-
orders and to recommend appropriate interventions and
treatments. We anticipate that further improvement in
prognosis will be based on increased understanding of
specific gene actions that will lead to definitive therapies.
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